SL4903 CAR-T therapy for relapsed or refractory multiple myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new cell therapy, SL4903 CAR-T, for people with multiple myeloma that has come back or stopped responding to earlier treatments. The goal is to see if this therapy can control the disease and help you feel better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have multiple myeloma that progressed or did not respond to at least one previous treatment line, including standard drugs like proteasome inhibitors, IMiDs, or anti-CD38 antibodies.
- Your disease is measurable (e.g., blood or urine M-protein levels, or visible soft tissue masses).
- You are in fairly good general health (ECOG 0-2) and have adequate organ function (heart, kidneys, liver, lungs).
- You have not had prior BCMA- or GPRC5D-directed CAR-T therapy.
- You do not have active central nervous system involvement or other serious uncontrolled conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new type of cell therapy called CAR-T, which uses your own immune cells to fight the cancer. It is for people with multiple myeloma that has come back or not responded to at least three previous treatments.
This trial tests a CAR-T cell therapy for multiple myeloma that has come back or not responded to at least three prior treatments. It aims to see if this immunotherapy can help control the disease.
This trial tests a new treatment called CAR-T cell therapy for people with multiple myeloma that has come back or not responded to other treatments. The treatment uses your own immune cells, modified in a lab to attack the cancer, and may be an option after a stem cell transplant has not worked.
This study tests a new type of immune cell therapy (CAR T-cells) for people with advanced multiple myeloma that has relapsed or not responded to standard treatments. The goal is to see if this therapy is safe and to understand its potential benefits.
This trial tests a new CAR-T cell therapy (a type of immune cell treatment) for people with multiple myeloma that has come back or not responded to several prior treatments. It aims to see if this therapy can help control the disease.
This trial tests a new type of immunotherapy called CAR T-cell therapy for people with multiple myeloma that has returned or not responded to standard treatments. The therapy uses your own immune cells, modified to attack the cancer, which may help you achieve a remission.
Hear when a new Relapsed and Refractory Multiple Myeloma (RRMM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.